Health Canada — Medical Devices · Canada · 2015-07-21 · Type II
🏛Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Archived by the issuing authority — kept for reference
Reported risk: A review of the 2-year follow-up data of engager European pivotal trial has shown that 16 of 32 subjects implanted with a 23mm device have a mean gradient of = 20 MMHG at some point after the implant (average mean gradient at 2-year follow up: 22.0 ? 7.5 MMHG). Gradient is a measure of the resistance to flow through the valve. A mean gradient of 20-40 MMHG is associated with mild stenosis (narrowing of the valve) per the valve academic research consortium (VARC) -2 guideline. No interventions, balloon valvuloplasty, or surgical replacement were performed related to the elevated gradient on the 16 study patients. As a result of these data, Medtronic has made the decision to voluntarily discontinue sales and distribution of the 23mm Bioprosthesis permanently. This recall affects only the 23mm Engager Bioprosthesis.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.